ES2702722T3 - Métodos y kits para cribar pacientes con cáncer - Google Patents

Métodos y kits para cribar pacientes con cáncer Download PDF

Info

Publication number
ES2702722T3
ES2702722T3 ES13745117T ES13745117T ES2702722T3 ES 2702722 T3 ES2702722 T3 ES 2702722T3 ES 13745117 T ES13745117 T ES 13745117T ES 13745117 T ES13745117 T ES 13745117T ES 2702722 T3 ES2702722 T3 ES 2702722T3
Authority
ES
Spain
Prior art keywords
cancer
patients
gene
expression
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13745117T
Other languages
English (en)
Spanish (es)
Inventor
Jérome Galon
Franck Pages
Bernhard Mlecnik
Gabriela Bindea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Descartes filed Critical Assistance Publique - Hôpitaux de Paris
Application granted granted Critical
Publication of ES2702722T3 publication Critical patent/ES2702722T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES13745117T 2012-08-06 2013-08-05 Métodos y kits para cribar pacientes con cáncer Active ES2702722T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305975 2012-08-06
PCT/EP2013/066425 WO2014023706A1 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Publications (1)

Publication Number Publication Date
ES2702722T3 true ES2702722T3 (es) 2019-03-05

Family

ID=46762994

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13745117T Active ES2702722T3 (es) 2012-08-06 2013-08-05 Métodos y kits para cribar pacientes con cáncer

Country Status (13)

Country Link
US (2) US20150218650A1 (enExample)
EP (2) EP2880180B1 (enExample)
JP (2) JP6559566B2 (enExample)
AU (1) AU2013301609B2 (enExample)
CA (1) CA2881389C (enExample)
DK (1) DK2880180T3 (enExample)
ES (1) ES2702722T3 (enExample)
LT (1) LT2880180T (enExample)
PL (1) PL2880180T3 (enExample)
PT (1) PT2880180T (enExample)
SG (1) SG11201500922RA (enExample)
TR (1) TR201819211T4 (enExample)
WO (1) WO2014023706A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
SG10202005315SA (en) * 2014-08-19 2020-07-29 Nat Univ Corporation Okayama Univ Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist
EP3240908A2 (en) * 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
JP7281903B2 (ja) * 2016-05-09 2023-05-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 固形腫瘍を有する患者をクラス分けするための方法
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
KR102350221B1 (ko) 2018-03-22 2022-01-14 스미또모 덴꼬오 하드메탈 가부시끼가이샤 표면 피복 절삭 공구 및 그 제조 방법
EP3861137A4 (en) * 2018-10-01 2022-07-13 Nantomics, LLC Evidence based selection of patients for clinical trials using histopathology
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
US7711492B2 (en) * 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
EP1893241A2 (en) 2005-04-28 2008-03-05 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CN104090095B (zh) 2005-11-23 2016-06-01 文塔纳医疗系统公司 分子缀合物
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
ES2816625T3 (es) * 2010-09-24 2021-04-05 Niels Grabe Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer
EP2663650B1 (en) * 2011-01-11 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the outcome of a cancer in a patient by analysing gene expression

Also Published As

Publication number Publication date
EP3470531A1 (en) 2019-04-17
CA2881389C (en) 2022-01-04
JP2019176880A (ja) 2019-10-17
LT2880180T (lt) 2019-01-25
TR201819211T4 (tr) 2019-01-21
WO2014023706A1 (en) 2014-02-13
US20150218650A1 (en) 2015-08-06
AU2013301609A1 (en) 2015-02-26
AU2013301609B2 (en) 2019-03-14
CA2881389A1 (en) 2014-02-13
PT2880180T (pt) 2018-12-27
EP2880180A1 (en) 2015-06-10
JP6559566B2 (ja) 2019-08-14
PL2880180T3 (pl) 2019-04-30
DK2880180T3 (en) 2019-01-14
EP2880180B1 (en) 2018-10-03
JP2015530877A (ja) 2015-10-29
JP6995091B2 (ja) 2022-01-14
SG11201500922RA (en) 2015-04-29
US20200299784A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
US12291752B2 (en) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
ES2808004T3 (es) Métodos para clasificar pacientes con un cáncer sólido
US20200299784A1 (en) Methods and kits for screening patients with cancer
US20250320564A1 (en) Methods and kits for treatment of cancer patients who are good responders to antitumoral treatment
JP2022174309A (ja) がんの重症度を評価するためのｔｉｍ－３
KR102431271B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
JP2022536075A (ja) 処置レジメンを調節する方法
HK40007449A (en) Methods for classifying patients with a solid cancer
HK40007449B (en) Methods for classifying patients with a solid cancer
BR112018072993B1 (pt) Método in vitro para o prognóstico do tempo de sobrevivência de um paciente que sofre de um câncer sólido e método in vitro para avaliar a capacidade de resposta de um paciente que sofre de um câncer sólido a um tratamento antitumoral